Refactory/Recurrent Prostate Cancer


Zytiga Approved for Prostate Cancer (05-4-2011)

The US Food and Drug Administration (FDA) has approved Zytiga™ (abiraterone acetate) for the treatment of advanced prostate cancer. The approval came two months earlier than expected. Prostate cancer is a hormonally sensitive disease that can often... Continue Reading

Intermittent Hormone Therapy Effective for Prostate Cancer (04-28-2011)

For men who experience a PSA recurrence (rise in prostate-specific antigen levels) after radiation therapy for prostate cancer, hormone therapy given intermittently (with breaks) appears to be as effective as hormone therapy given continuously. These... Continue Reading

Body Weight and C-Peptide Levels Associated with Risk of Dying from Prostate Cancer (10-20-2008)

Body Weight and C-Peptide Levels Associated with Risk of Dying from Prostate Cancer Excess body weight coupled with a high C-peptide level among men with prostate cancer is associated with an increased risk of death from the disease. These results were... Continue Reading